Patients with suspected or confirmed EVD who present with fever may concurrently have uncomplicated malaria. Managing both conditions simultaneously is essential — empiric antimalarial therapy is indicated for all febrile EVD patients.
EVD with uncomplicated malaria is a recognised co-presentation requiring dedicated antimalarial management alongside EVD care. Empiric antimalarial therapy should be administered to all febrile patients with suspect and confirmed EVD, regardless of whether malaria has been laboratory-confirmed at the time of initiation.
The protocol specifies an artemisinin-based combination antimalarial given as a complete fixed-duration course. Weight- and age-based dosing applies across all patient groups. The specific combination, dosing table, and stopping criteria are defined in the full structured protocol.
Empiric antimalarial therapy should be administered to all febrile patients with suspect and confirmed EVD.
Treatment with artesunate-amodiaquine or pyronaridine-artesunate.
A full course of 3 days must be given for all age/weight groups.
View source ↗